Guardant Health (NASDAQ: GH) reported Q2 EPS of ($0.42), $0.33 better than the analyst estimate of ($0.75). Revenue for the quarter came in at $334.97 million versus the consensus estimate of $314.23 million.

GUIDANCE:

Guardant Health sees FY2026 revenue of $1.34-1.36 billion, versus the consensus of $1.31 billion.

For earnings history and earnings-related data on Guardant Health (GH) click here.